Stammdaten
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
Unternehmen & Branche
| Name | Regen BioPharma Inc |
|---|---|
| Ticker | RGBP |
| CIK | 0001589150 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | 75886M102 |
|---|---|
| ISIN | US75886M1027 |
| Typ | Common Stock |
| Marktkapitalisierung | 15.777 USD |
| Beta | 2,87 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 59,065 | -967,853 | -0.01 | 237,076 | -6,572,997 |
| 2025-09-30 | 10-Q | -702,033 | 274,628 | -6,281,183 | ||
| 2025-09-30 | 10-K | 236,561 | -1,274,502 | -0.05 | 274,628 | -6,281,183 |
| 2025-06-30 | 10-Q | 59,065 | -167,292 | -0.01 | 196,841 | -5,815,691 |
| 2025-03-31 | 10-Q | 59,065 | -19,354 | 0.00 | 169,482 | -5,698,399 |
| 2024-12-31 | 10-Q | 59,065 | -515,384 | -0.13 | 191,416 | -5,679,043 |
| 2024-09-30 | 10-K | 236,560 | -668,255 | -0.16 | 161,084 | -5,217,372 |
| 2024-06-30 | 10-Q | 59,065 | -130,120 | -0.03 | 170,150 | -5,157,713 |
| 2024-03-31 | 10-Q | 31,640 | -122,454 | -0.03 | 140,770 | -5,175,962 |
| 2023-12-31 | 10-Q | 31,640 | -144,933 | -0.04 | 159,528 | -5,241,483 |
| 2023-09-30 | 10-K | 126,560 | 1,156,507 | 0.29 | 353,617 | -5,103,999 |
| 2023-06-30 | 10-Q | 59,065 | -99,218 | -0.03 | 285,196 | -5,028,973 |
| 2023-03-31 | 10-Q | 31,640 | -54,978 | 406,635 | -4,929,755 | |
| 2022-12-31 | 10-Q | 31,640 | 1,635,730 | 0.45 | 414,108 | -4,884,827 |
| 2022-09-30 | 10-K | 125,517 | 2,443,531 | 0.71 | 559,002 | -8,036,059 |
| 2022-06-30 | 10-Q | 31,292 | 66,958,167 | 689,693 | -8,349,684 | |
| 2022-03-31 | 10-Q | 30,945 | -67,081,589 | 630,869 | -76,749,430 | |
| 2021-12-31 | 10-Q | 31,640 | 2,644,980 | 735,241 | -9,755,969 | |
| 2021-09-30 | 10-K | 61,194 | -6,765,233 | 1,212,099 | -13,485,877 | |
| 2021-06-30 | 10-Q | 29,206 | -7,489,114 | 1,433,656 | -12,411,685 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 30.09.2024. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| THOMPSON INVESTMENT MANAGEMENT, INC. | 12 | 3 | 100.00 |